CDT Equity Inc. Warrant (CDTTW) Stock Price
CDTTWStock
$0.01
Market Cap—
P/E—
PEG Ratio—
Div yield—
Beta3.01
CDTTW Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-27.52%
Price vs S&P 500 (4W)-13.60%
VGM Score52.69
Industry Peers — Pharmaceuticals(571)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CDTTWCDT Equity Inc. Warrant | — | — | C | $0.01 |
| LLYEli Lilly & Co. | D | B | B | $1233.66 |
| JNJJohnson & Johnson | D | C | B | $273.14 |
| ABBVABBVIE INC. | D | C | B | $265.79 |
| MRKMerck & Co., Inc. | D | C | A | $156.45 |
| NVSNovartis AG | C | C | C | $159.98 |
| AZNAstraZeneca PLC | C | B | C | $169.66 |
| NVONovo-Nordisk A/S | B | C | C | $48.66 |
| ABTAbbott Laboratories | C | C | B | $116.13 |
| PFEPfizer Inc. | C | D | C | $28.57 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $552.85 |
About CDT Equity Inc. Warrant
CDT Equity Inc is a clinical-stage biopharmaceutical company developing treatments for unmet medical needs with a focus on autoimmune diseases and male infertility. Its lead program is a glucokinase activator in Phase II development for conditions including uveitis, Hashimoto's Thyroiditis, preterm labor, and transplant rejection. The company also has an early-stage MPO inhibitor program targeting idiopathic male infertility.